Lloyd G Simonson

US Patent:

6599691, Jul 29, 2003

Filed:

Feb 24, 1997

Appl. No.:

09/044214

Inventors:

Stephen Alden Ralls - McLean VA
Lloyd Grant Simonson - Spring Grove IL

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

C12Q 100

US Classification:

435 4, 435 5, 435 77, 435 722, 435 792, 435863, 435975, 435 71, 435 79

Abstract:

A rapid, non-invasive, semi-quantitative immunoassay of saliva has been developed to aid in the diagnosis of diseases, e. g. , using saliva to detect subjects actively or previously infected with , a causative organism of tuberculosis. The semi-quantitative assay comprises spotting disease-related antigens on the surface of a solid substrate; contacting the solid substrate with a saliva sample which, in positive subjects, contains primary antibodies to the disease-related antigens; contacting the primary antibodies with a label capable of being detected; and detecting and reading the label whereby exposure to the antigens is determined. The device for conducting these assays is a frame or support which holds a solid substrate capable of immobilizing the antigens of interest while permitting drainage of other materials or fluids away from the immobilized antigens. A less rapid, quantitative assay has also been developed by adapting the rapid, semi-quantitative assay to an enzyme linked immunosorbant assay thereby providing a quantitative assay capable of assessing multiple saliva samples simultaneously.

US Patent:

6841159, Jan 11, 2005

Filed:

Jan 30, 2002

Appl. No.:

10/061036

Inventors:

Lloyd G. Simonson - Spring Grove IL, US

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

A61K 3904
A61K 902

US Classification:

4242481, 4241301, 4241641, 4241681, 4241841, 4242341, 435 4, 435 71, 435 732

Abstract:

An assay method and kit is disclosed for detecting the presence of at least one predesignated, target antibody to a mycobacterium in a sample selected from one or more patient bodily fluids. The method comprises the following steps: (a) contacting the sample of one or more patient bodily fluids with at least one mycobacterium antigen on a lateral-flow assay membrane to bind to the target antibody in the sample; (b) previously, simultaneously or subsequently to step (a), binding the at least one mycobacterium antigen with a conjugated label producing a detectable signal; and (c) detecting the signal whereby the presence of the target antibody is determined in the sample by the intensity or presence of the signal. The method can further comprise the step of evaluating immunization status of the patient from whom the sample came by comparing the signal or lack thereof with immunizations previously received by the patient and in comparison to a known standard control. In a preferred embodiment, the mycobacterium antigen specifically binds to specific antibodies.

US Patent:

6927068, Aug 9, 2005

Filed:

Jan 30, 2002

Appl. No.:

10/060605

Inventors:

Lloyd G. Simonson - Spring Grove IL, US
John R. Kelly - Rockville MD, US

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

G01N033/53

US Classification:

436518, 436517, 436514, 436528, 436530, 436541, 436810, 422 56, 422 57, 422 58, 422 59, 422 60, 435 71, 435 793, 435 794, 435970, 43525231

Abstract:

An assay method and kit for detecting the presence of a predesignated, target IgG antibody in a sample selected from one or more patient bodily fluids. The method comprises the following steps: (a) contacting the sample of one or more patient bodily fluids with a membrane-bound recombinant protective antigen to bind to the target IgG antibody in the sample; (b) previously, simultaneously or subsequently to step (a), binding the protective antigen (PA) with a conjugated label producing a detectable signal; and (c) detecting the signal whereby the presence of the target IgG antibody is determined in the sample by the intensity of the signal. The method can further comprise the step of evaluating immunization status of the patient from whom the sample came by comparing the signal or lack thereof with immunizations previously received by the patient. In a preferred embodiment, the recombinant protective antigen (PA) specifically binds to anthrax protective antigen-specific IgG antibodies. Preferably, the immunoassay of the present invention comprises a lateral-flow assay comprising a membrane, a conjugated label pad, and a recombinant protective antigen (PA) bound to the membrane.

US Patent:

7408640, Aug 5, 2008

Filed:

Nov 5, 2003

Appl. No.:

10/700868

Inventors:

Malford E. Cullum - Grayslake IL, US
Lloyd G. Simonson - Spring Grove IL, US
Sylvia Z. Schade - Riverside IL, US
Linda A. Lininger - Grayslake IL, US
Alan L. McArthur - Mokena IL, US

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

G01J 3/00
G01J 4/00
C12M 1/00
C12M 3/00

US Classification:

356368, 356300, 356364, 4352831, 4352871, 4352872

Abstract:

The inventive subject matter relates to a method for detecting the presence of a biological substance of interest in a test sample of saliva or oral fluid, comprising combining said test sample with a fluorescence-labeled ligand to said biological substance and detecting a change in the fluorescence polarization of said test sample produced by binding of said fluorescence-labeled ligand to said biological substance. In one aspect of the inventive subject matter, said method comprises additional steps for comparing the fluorescence polarization of said test sample with the fluorescence polarization of a control solution. Also provided is a miniaturized, portable apparatus for measuring the fluorescence polarization of a liquid sample.

US Patent:

7504202, Mar 17, 2009

Filed:

Mar 26, 2004

Appl. No.:

10/809877

Inventors:

Malford E. Cullum - Grayslake IL, US
Paul Hine - Holt MI, US
Lloyd G. Simonson - Spring Grove IL, US
Chun N. Shih - East Lansing MI, US
Diane R. Bienek - Lindenhurst IL, US
Sukjoon Park - Germantown MD, US
Linda A. Lininger - Grayslake IL, US

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

C12Q 1/00

US Classification:

435 4, 435 793, 435 34, 436518, 530350

Abstract:

The inventive subject matter relates to a competitive method for estimating the concentration in a sample of a protein or antibody thereof selected from the group consisting of protective antigen (PA), lethal factor (LF) and edema factor (EF). The method may employ the use of Fluorescence Polarization, FLT or FRET. The competitive methods are capable of detecting a target protein within 5 minutes within the range of 0. 1 to 10. 0 nM. The methods provide for the rapid detection and quantitation of bacteria, bacterial antigen or antibody in culture media or broth of growing cultures of bacteria, including by fluorescent methods.

US Patent:

8114582, Feb 14, 2012

Filed:

Jun 27, 2008

Appl. No.:

12/163412

Inventors:

Malford E. Cullum - Grayslake IL, US
Lloyd G. Simonson - Spring Grove IL, US
Sylvia Z. Schade - Riverside IL, US
Linda A. Lininger - Grayslake IL, US
Alan L. McArthur - Mokena IL, US

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

C12Q 1/00
G01N 33/53
G01N 33/554
G01N 3/00
A61K 39/00
A61K 39/07
A61K 39/04

US Classification:

435 4, 435 71, 435 732, 435 792, 4241841, 4242461, 4242481

Abstract:

The inventive subject matter relates to a method for detecting the presence of a biological substance of interest in a test sample of saliva or oral fluid, comprising combining said test sample with a fluorescence-labeled ligand to said biological substance and detecting a change in the fluorescence polarization of said test sample produced by binding of said fluorescence-labeled ligand to said biological substance. In one aspect of the inventive subject matter, said method comprises additional steps for comparing the fluorescence polarization of said test sample with the fluorescence polarization of a control solution. Also provided is a miniaturized, portable apparatus for measuring the fluorescence polarization of a liquid sample.

US Patent:

41384768, Feb 6, 1979

Filed:

Aug 3, 1977

Appl. No.:

5/821275

Inventors:

Lloyd G. Simonson - Waukegan IL
Burton L. Lamberts - Libertyville IL

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

A61K 728

US Classification:

424 50

Abstract:

An oral therapeutic substance is formed by modifying a plaque-dispersing enzyme to control and reduce the occurrence of dental caries and periodontal diseases. In one embodiment, the modification is performed by introducing a suitable complexing reagent in combination with carrier and plaque-dispersing glucanohydrolase molecules to molecularly alter the glucanohydrolase. The modification, while having insignificant effects on the catalytic activity of the enzyme, will increase the binding capability of the enzyme to substances of which the tooth surface is formed. The activity of the enzyme on the tooth surface will therefore be maintained for longer periods of time to combat plaque build-up.

US Patent:

60156813, Jan 18, 2000

Filed:

Dec 12, 1996

Appl. No.:

8/766203

Inventors:

Stephen Alden Ralls - Great Lakes IL
Lloyd Grant Simonson - Spring Grove IL

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

G01N 33554
G01N 3353
G01N 33537
G01N 33543

US Classification:

435 732

Abstract:

An assay method and kit for detecting specific oral cariogenic bacteria,. , mutans streptococci, Lactobacillus sp. and Actinomyces sp. , separately or in combination, comprising gathering a sample suspected of containing cariogenic bacteria; treating the sample with a stripping buffer to remove host antibodies from bacteria present in the sample; retaining the treated bacteria on a blocked solid phase substrate; reacting the retained bacteria with a primary antibody specific for the desired cariogenic bacteria; reacting the primary antibody with a conjugated label producing a detectable signal; and detecting the signal whereby the presence of the desired cariogenic bacteria is determined in the sample. The device for conducting these assays is a frame or support which holds a solid substrate capable of retaining the bacteria of interest while permitting drainage of other materials or fluids away from the retained bacteria.